Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

23.05.14	CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union (Businesswire)
12.05.14	Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine (Businesswire)
12.05.14	Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World (Businesswire)
01.05.14	New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients (Businesswire)
30.04.14	Biogen Idec Says New Data Reinforce Efficacy Of TECFIDERA In Patients With RRMS (RTTNews)
30.04.14	New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity (Businesswire)
29.04.14	Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting (Businesswire)
23.04.14	Biogen Idec Q1 Profit Up 12%, But Misses Estimates; Lifts FY14 View (RTTNews)
23.04.14	Biogen Idec Q1 Adj. EPS Miss Estimates; Lifts FY14 Forecast - Quick Facts (RTTNews)
23.04.14	Earnings Watch For April 23 (BA, PG, AAPL, FB, QCOM, TXN) (RTTNews)
14.04.14	Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting (Businesswire)
10.04.14	Biogen Idec Reports Positive Top-line Results Of Kids A-LONG Phase 3 Study (RTTNews)
10.04.14	Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer (Businesswire)
10.04.14	Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A (Businesswire)
28.03.14	FDA Approves Biogen Idec's Hemophilia B Drug Alprolix (RTTNews)
24.03.14	Biogen Idec's Alprolix Gets Health Canada Approval For Hemophilia B (RTTNews)
18.03.14	Biogen Idec Receives Notification of PDUFA Date Extension for Plegridy™ (Peginterferon Beta-1a) (Businesswire)
05.03.14	Eisai, Biogen Idec To Work On Two Clinical Candidates For Alzheimer's Disease (RTTNews)
05.03.14	Eisai and Biogen Idec Enter Collaboration to Develop and Commercialize Alzheimer’s Disease Treatments (Businesswire)
15.02.14	Biogen Idec Chairman William Young To Retire - Quick Facts (RTTNews)
15.02.14	William D. Young To Retire From Biogen Idec’s Board of Directors (Businesswire)
10.02.14	Merck, Samsung Bioepis To Develop & Commercialize Insulin Glargine Candidate (RTTNews)
03.02.14	Biogen Idec: EU Oks Tecfidera As First-Line Oral Treatment For MS - Quick Facts (RTTNews)
30.01.14	UCB Granted Rights To Distribute Biogen's Products In Asia (RTTNews)
30.01.14	Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia (Businesswire)
17.12.13	Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe (Businesswire)
09.12.13	Biogen Reports Additional Results From Phase 3 Pediatric Studies (RTTNews)
04.12.13	The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX™ Effectively Controlled Bleeding in Hemophilia B Patients (Businesswire)
24.11.13	Biogen Idec Gets Regulatory Protection For MS Drug Tecfidera In Europe (RTTNews)
22.11.13	Biogen Idec Gets European Protection For MS Drug Tecfidera - Quick Facts (RTTNews)
22.11.13	Pre-market Movers For Nov 22 (ARIA, ARUN, BIIB, POZN, FL, SPLK, ROST) (RTTNews)
22.11.13	CHMP Determines Dimethyl Fumarate in TECFIDERA® to be a New Active Substance in the European Union (Businesswire)
21.11.13	PETX On The Move, IMGN To Pocket $5Mln, RGLS Gets Richer, MYGN Does It Again (RTTNews)
12.11.13	Isis Pharmaceuticals Gets $1.5 Mln Milestone Payment From Biogen - Quick Facts (RTTNews)
12.11.13	Galapagos Unit Enters 3-year Collaboration Deal With Biogen Idec (RTTNews)
28.10.13	Pre-market Movers For Oct 28 (BIIB, MRK, MOS, BKW, DNDN, CLVS, SOHU, CYOU, SNTA) (RTTNews)
28.10.13	Biogen Tops Estimates On MS Drug Sales, Boosts 2013 Outlook (RTTNews)
28.10.13	Biogen Idec Q3 Profit Rises; Lifts Full Year Guidance - Quick Facts (RTTNews)
28.10.13	Earnings Watch For October 28 (MRK, PMCS, STX, SANM, AAPL, PPS) (RTTNews)
11.10.13	Scheduled Earnings Releases, Survey and Study Results, and Enrollment into Clinical Trial - Research Report on Biogen Idec, Questcor, Medivation, Agenus, and Arrowhead Research (PR Newswire)
08.10.13	Critical Alerts For Coca-Cola, Biogen Idec, Hewlett-Packard, Yum! Brands, and Sarepta Therapeutics Released By InvestorsObserver (PR Newswire)
04.10.13	Conference Calls, Philanthropic Activities, Clinical Trial Data, and Regulatory Approvals - Research Report on Celgene, UnitedHealth, Biogen Idec, WellPoint, and Medtronic (PR Newswire)
04.10.13	New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients (Businesswire)
03.10.13	Biogen Idec: New Analyses Show Tysabri Given Earlier Reduces MS Disease Activity (RTTNews)
03.10.13	New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity (Businesswire)
02.10.13	Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus (PR Newswire)
01.10.13	Biogen Says New Data Show Significant Improvements With Plegridy (RTTNews)
01.10.13	New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY™ (Peginterferon Beta-1a) (Businesswire)
01.10.13	Neue Auswertungen von Studiendaten zeigen signifikante klinische und kernspintomographische Verbesserungen bei Behandlung mit PLEGRIDY™ (Peginterferon Beta-1a) (Businesswire)
24.09.13	Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

29.11.24		Gute Stimmung in New York: Börsianer lassen Dow Jones mittags steigen
29.11.24		Starker Wochentag in Frankfurt: TecDAX zum Handelsende mit Zuschlägen
29.11.24		Gewinne in Europa: Euro STOXX 50 präsentiert sich zum Ende des Freitagshandels fester
29.11.24		DAX-Handel aktuell: DAX legt zum Handelsende zu
29.11.24		Freundlicher Handel: SDAX zum Handelsende stärker
29.11.24		XETRA-Handel: LUS-DAX schlussendlich mit Zuschlägen

29.11.24

Gute Stimmung in New York: Börsianer lassen Dow Jones mittags steigen

29.11.24

Starker Wochentag in Frankfurt: TecDAX zum Handelsende mit Zuschlägen

29.11.24

Gewinne in Europa: Euro STOXX 50 präsentiert sich zum Ende des Freitagshandels fester

29.11.24

DAX-Handel aktuell: DAX legt zum Handelsende zu

29.11.24

Freundlicher Handel: SDAX zum Handelsende stärker

29.11.24

XETRA-Handel: LUS-DAX schlussendlich mit Zuschlägen